Marché mondial du syndrome d’insensibilité complète aux androgènes – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché                              

Le syndrome d'insensibilité aux androgènes (SIA) est une maladie génétique héréditaire qui touche environ une personne sur 20 000. Le syndrome d'insensibilité totale aux androgènes empêche les cellules du corps de réagir aux androgènes, ou hormones mâles. Certaines personnes sont insensibles aux androgènes dans une certaine mesure. Le syndrome d'insensibilité totale aux androgènes a un impact sur le développement sexuel avant et après la naissance, ainsi que pendant la puberté. Ce trouble touche les personnes génétiquement masculines (un chromosome X et un chromosome Y) mais qui ne réagissent pas aux hormones mâles. Par conséquent, leurs organes génitaux externes et leurs seins sont généralement féminins. Elles n'ont pas d'utérus ni de col de l'utérus, ce qui les empêche d'avoir leurs règles ou d'avoir des enfants.

Français Data Bridge Market Research analyse que le marché complet du syndrome d’insensibilité aux androgènes était évalué à 491,43 millions USD en 2021 et devrait atteindre 726,07 millions USD d’ici 2029, enregistrant un TCAC de 5,0 % au cours de la période de prévision de 2022 à 2029. En plus des informations sur le marché telles que la valeur du marché, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l’équipe de recherche sur le marché Data Bridge comprend également une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Portée du rapport et segmentation du marché

Market Definition

Complete androgen insensitivity syndrome (CAIS) is a genetic disorder in which a child is genetically male but has female sex traits. CAIS is a sex development condition (DSD). The testes are removed either after puberty when feminization is complete or before puberty, and estrogen treatment is administered at puberty. To avoid dyspareunia, vaginal dilation may be recommended. Bone mineral density scans are required every five years for adults. Disclosure necessitates psychological assistance.

Complete Androgen Insensitivity Syndrome Market Dynamics

Drivers

• Rise in the number of cases of complete androgen insensitivity syndrome?

The surging number of complete androgen insensitivity syndrome? cases is anticipated to be a major factor driving the market's growth rate during the forecast period of 2022-2029. Males who inherit a faulty gene from their mothers, known as the androgen receptor (AR) gene, have a 1 in 4 chance of having androgen insensitivity syndrome (AIS). Females can inherit the gene and carry it, but they will not develop AIS. Complete androgen insensitivity syndrome is caused by a defective X-linked gene, which means it is a gene on the X chromosome that is passed down from mother to kid. This gene does not produce androgen receptors. These are the cells that help your body respond to androgens including testosterone.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of the complete androgen insensitivity syndrome? market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising government initiatives to spread awareness and sedentary lifestyle of people will result in the expansion of the complete androgen insensitivity syndrome? market. Along with this, favourable reimbursement policies and rising adoption of early diagnostic among people will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the complete androgen insensitivity syndrome? market growth.

Moreover, the market's growth is fueled by rising technological advancement in diagnostic methods and emerging new markets. These factors will provide beneficial opportunities for the complete androgen insensitivity syndrome? market growth.

Restraints/Challenges

On the other hand, the high cost associated with the treatment and diagnosis will obstruct the growth rate of the market. The lack of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the market's complete androgen insensitivity syndrome. Additionally, lack of awareness among people and unfavorable healthcare policies will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This complete androgen insensitivity syndrome? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the complete androgen insensitivity syndrome? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Androgen insensitivity is a rare condition. Partial androgen insensitivity syndrome affects about 1 in 99,000 male infants, while complete androgen insensitivity syndrome impact 2 to 5 per 100,000.

Complete androgen insensitivity syndrome? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global Complete Androgen Insensitivity Syndrome Market Scope

The complete androgen insensitivity syndrome? market is segmented on the basis of symptoms, diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Symptoms

• Abnormally Tall Stature
• Little or No Pubic Hair
• Shallow Vagina
• Undescended Testicles
• Amenorrhea
• Others

Diagnosis

• Blood Test
• Genetic Testing
• Pelvic Ultrasound
• Others

Treatment

• Surgery
• Estrogen Replacement Therapy
• Genetic Counselling
• Hormone Medications
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Complete Androgen Insensitivity Syndrome Market Regional Analysis/Insights

The complete androgen insensitivity syndrome? market is analysed and market size insights and trends are provided by country, symptoms, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the complete androgen insensitivity syndrome? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the complete androgen insensitivity syndrome? market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing prevalence of androgen insensitivity syndrome? , and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, the growing presence of major key players will further propel the market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the development of healthcare infrastructure in this region. Also, rising government initiatives will further propel the market's growth rate in this region.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.   

Analyse du paysage concurrentiel et des parts de marché du syndrome d'insensibilité aux androgènes

Le paysage concurrentiel du marché du syndrome d'insensibilité aux androgènes complet ? fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché du syndrome d'insensibilité aux androgènes complet ?.

Certains des principaux acteurs opérant sur le marché du syndrome d'insensibilité complète aux androgènes sont :

• F. Hoffmann-La Roche SA (Suisse)
• Mylan NV (États-Unis)
• Sanofi (France)
• Pfizer Inc. (États-Unis)
• GlaxoSmithKline plc (Royaume-Uni)
• Novartis SA (Suisse)
• Bayer AG (Allemagne)
• Eli Lilly and Company (États-Unis)
• Merck & Co., Inc. (États-Unis)
• Allergan (Irlande)
• Abbott (États-Unis)
• Merck KGaA (Allemagne)
• Novo Nordisk A/S (Danemark)
• Genentech Inc. (États-Unis)
• Amgen Inc. (États-Unis)
• Endo International plc (Irlande)
• Hisamitsu Pharmaceutical Co., Inc. (Japon)

SKU-68494